Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,capitalSurplus,totalLiab,totalStockholderEquity,totalAssets,commonStock,otherCurrentAssets,retainedEarnings,treasuryStock,totalCurrentLiabilities,totalCurrentAssets,longTermInvestments,netReceivables,longTermDebt,accountsPayable,otherCurrentLiab,changeToLiabilities,netBorrowings,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,totalCashFromOperatingActivities,changeToAccountReceivables,changeToNetincome,WC,language,region,quoteType,triggerable,quoteSourceName,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,dividendDate,trailingAnnualDividendRate,gmtOffSetMilliseconds,esgPopulated,tradeable,currency,marketState,trailingAnnualDividendYield,epsTrailingTwelveMonths,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,shortName,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,exchangeDataDelayedBy,exchange,priceHint,market,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (May 27, 2021) 4","Short Ratio (May 27, 2021) 4","Short % of Float (May 27, 2021) 4","Short % of Shares Outstanding (May 27, 2021) 4","Shares Short (prior month Apr 29, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,longBusinessSummary,city,phone,state,compensationAsOfEpochDate,country,website,maxAge,address1,fax,industry,address2
t0,DXR,15675186.0,4033880,,,908815,,921455,185415,72746,-117097,-117097,4428,-412,,,,-12640,72746,189843,0,1025913,,921455,921455,11384990.0,877689.0,15675186.0,16552875.0,53166.0,617800.0,14860033.0,-10623003.0,707000.0,880990.0,15671885.0,263190.0,170689.0,80000.0,,20304,-367019,864267,1399856,1231286,308900,-555367,-4644,-2892339,173990.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,2.713346,9.8574 - 9.9,9.597,9.36,9.9,11,12,finmb_265888,NYSE American,Daxor Corporation,USD,30301,18750,1.2774,0.14888112,8.58 - 17.58,-7.7226,-0.43928328,8.58,17.58,1515715200,0.03,-14400000,False,False,USD,REGULAR,0.0031259768,-0.423,3.886,9.494166,0.36323357,0.038258605,10.712608,-0.8552084,-0.07983195,39763568,2.5366445,15,America/New_York,EDT,Daxor Corporation,9.8574,1630506145,0.26039982,9.63,9.9,9.8574,2018,0,ASE,2,us_market,-1.08,,,17.58,8.58,9.49,10.71,30.3k,18.75k,4.03M,,1.31M,67.44%,5.02%,22.7k,2.04,0.59%,0.56%,15.99k,,,0.03,0.31%,,0.00%,"Jan 11, 2018","Jan 04, 2018",,,"Dec 30, 2020","Dec 30, 2020",0.00%,-127.79%,-1.37%,-11.99%,264.44k,0.07,-22.30%,264.44k,,-1.71M,-0.42,,,,797.69k,5.09,1.25,3.89,-2.45M,-501.49k,Value,10118,Healthcare,"Daxor Corporation, a medical device company, provides biotechnology and cryobanking services in the United States. The company offers BVA-100 Blood Volume Analyzer, an instrument that measures blood volume in human body. BVA-100 Blood Volume Analyzer is used to diagnose and treat patients in various medical and surgical conditions, including congestive heart failure, critical care medicine and intensive care unit medicine, hypertension, syncope, pre-operative blood screening for hidden anemia, anemia in cancer patients, kidney failure, and hyponatremia. It also provides semen banking, blood storage, andrology, and general lab testing services. Daxor Corporation has a cooperative research and development agreement with the Uniformed Services University of the Health Sciences for researching the effectiveness of BVA-100 diagnostic test on quantifying circulatory blood volume in the context of traumatic injury. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was founded in 1970 and is headquartered in New York, New York.",New York,212 330 8500,NY,1609372800,United States,http://www.daxor.com,86400,Empire State Building,212 244 0806,Medical Instruments & Supplies,Suite 7120 350 Fifth Avenue
t-1,DXR,15675186.0,4033880,,,908815,,921455,185415,72746,-117097,-117097,4428,-412,,,,-12640,72746,189843,0,1025913,,921455,921455,11384990.0,877689.0,15675186.0,16552875.0,53166.0,617800.0,14860033.0,-10623003.0,707000.0,880990.0,15671885.0,263190.0,170689.0,80000.0,,20304,-367019,864267,1399856,1231286,308900,-555367,-4644,-2892339,173990.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,2.713346,9.8574 - 9.9,9.597,9.36,9.9,11,12,finmb_265888,NYSE American,Daxor Corporation,USD,30301,18750,1.2774,0.14888112,8.58 - 17.58,-7.7226,-0.43928328,8.58,17.58,1515715200,0.03,-14400000,False,False,USD,REGULAR,0.0031259768,-0.423,3.886,9.494166,0.36323357,0.038258605,10.712608,-0.8552084,-0.07983195,39763568,2.5366445,15,America/New_York,EDT,Daxor Corporation,9.8574,1630506145,0.26039982,9.63,9.9,9.8574,2018,0,ASE,2,us_market,-1.08,,,17.58,8.58,9.49,10.71,30.3k,18.75k,4.03M,,1.31M,67.44%,5.02%,22.7k,2.04,0.59%,0.56%,15.99k,,,0.03,0.31%,,0.00%,"Jan 11, 2018","Jan 04, 2018",,,"Dec 30, 2020","Dec 30, 2020",0.00%,-127.79%,-1.37%,-11.99%,264.44k,0.07,-22.30%,264.44k,,-1.71M,-0.42,,,,797.69k,5.09,1.25,3.89,-2.45M,-501.49k,Value,10118,Healthcare,"Daxor Corporation, a medical device company, provides biotechnology and cryobanking services in the United States. The company offers BVA-100 Blood Volume Analyzer, an instrument that measures blood volume in human body. BVA-100 Blood Volume Analyzer is used to diagnose and treat patients in various medical and surgical conditions, including congestive heart failure, critical care medicine and intensive care unit medicine, hypertension, syncope, pre-operative blood screening for hidden anemia, anemia in cancer patients, kidney failure, and hyponatremia. It also provides semen banking, blood storage, andrology, and general lab testing services. Daxor Corporation has a cooperative research and development agreement with the Uniformed Services University of the Health Sciences for researching the effectiveness of BVA-100 diagnostic test on quantifying circulatory blood volume in the context of traumatic injury. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was founded in 1970 and is headquartered in New York, New York.",New York,212 330 8500,NY,1609372800,United States,http://www.daxor.com,86400,Empire State Building,212 244 0806,Medical Instruments & Supplies,Suite 7120 350 Fifth Avenue
t-2,DXR,11155623.0,4033880,,,-1774151,,-1774151,111347,59474,-51873,-51873,4428,-3789,,,,0,59474,111347,0,-1722278,,-1774151,-1774151,11170908.0,3851852.0,11155623.0,15007475.0,53166.0,2799712.0,13017122.0,-13085573.0,2947125.0,3018194.0,11989281.0,218482.0,904727.0,3975.0,121650.0,-37388,-218912,668453,-1399856,887365,308900,-668453,6364,2536578,71069.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,2.713346,9.8574 - 9.9,9.597,9.36,9.9,11,12,finmb_265888,NYSE American,Daxor Corporation,USD,30301,18750,1.2774,0.14888112,8.58 - 17.58,-7.7226,-0.43928328,8.58,17.58,1515715200,0.03,-14400000,False,False,USD,REGULAR,0.0031259768,-0.423,3.886,9.494166,0.36323357,0.038258605,10.712608,-0.8552084,-0.07983195,39763568,2.5366445,15,America/New_York,EDT,Daxor Corporation,9.8574,1630506145,0.26039982,9.63,9.9,9.8574,2018,0,ASE,2,us_market,-1.08,,,17.58,8.58,9.49,10.71,30.3k,18.75k,4.03M,,1.31M,67.44%,5.02%,22.7k,2.04,0.59%,0.56%,15.99k,,,0.03,0.31%,,0.00%,"Jan 11, 2018","Jan 04, 2018",,,"Dec 30, 2020","Dec 30, 2020",0.00%,-127.79%,-1.37%,-11.99%,264.44k,0.07,-22.30%,264.44k,,-1.71M,-0.42,,,,797.69k,5.09,1.25,3.89,-2.45M,-501.49k,Value,10118,Healthcare,"Daxor Corporation, a medical device company, provides biotechnology and cryobanking services in the United States. The company offers BVA-100 Blood Volume Analyzer, an instrument that measures blood volume in human body. BVA-100 Blood Volume Analyzer is used to diagnose and treat patients in various medical and surgical conditions, including congestive heart failure, critical care medicine and intensive care unit medicine, hypertension, syncope, pre-operative blood screening for hidden anemia, anemia in cancer patients, kidney failure, and hyponatremia. It also provides semen banking, blood storage, andrology, and general lab testing services. Daxor Corporation has a cooperative research and development agreement with the Uniformed Services University of the Health Sciences for researching the effectiveness of BVA-100 diagnostic test on quantifying circulatory blood volume in the context of traumatic injury. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was founded in 1970 and is headquartered in New York, New York.",New York,212 330 8500,NY,1609372800,United States,http://www.daxor.com,86400,Empire State Building,212 244 0806,Medical Instruments & Supplies,Suite 7120 350 Fifth Avenue
t-3,DXR,11155623.0,4033880,,,-1774151,,-1774151,111347,59474,-51873,-51873,4428,-3789,,,,0,59474,111347,0,-1722278,,-1774151,-1774151,11170908.0,3851852.0,11155623.0,15007475.0,53166.0,2799712.0,13017122.0,-13085573.0,2947125.0,3018194.0,11989281.0,218482.0,904727.0,3975.0,121650.0,-37388,-218912,668453,-1399856,887365,308900,-668453,6364,2536578,71069.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,2.713346,9.8574 - 9.9,9.597,9.36,9.9,11,12,finmb_265888,NYSE American,Daxor Corporation,USD,30301,18750,1.2774,0.14888112,8.58 - 17.58,-7.7226,-0.43928328,8.58,17.58,1515715200,0.03,-14400000,False,False,USD,REGULAR,0.0031259768,-0.423,3.886,9.494166,0.36323357,0.038258605,10.712608,-0.8552084,-0.07983195,39763568,2.5366445,15,America/New_York,EDT,Daxor Corporation,9.8574,1630506145,0.26039982,9.63,9.9,9.8574,2018,0,ASE,2,us_market,-1.08,,,17.58,8.58,9.49,10.71,30.3k,18.75k,4.03M,,1.31M,67.44%,5.02%,22.7k,2.04,0.59%,0.56%,15.99k,,,0.03,0.31%,,0.00%,"Jan 11, 2018","Jan 04, 2018",,,"Dec 30, 2020","Dec 30, 2020",0.00%,-127.79%,-1.37%,-11.99%,264.44k,0.07,-22.30%,264.44k,,-1.71M,-0.42,,,,797.69k,5.09,1.25,3.89,-2.45M,-501.49k,Value,10118,Healthcare,"Daxor Corporation, a medical device company, provides biotechnology and cryobanking services in the United States. The company offers BVA-100 Blood Volume Analyzer, an instrument that measures blood volume in human body. BVA-100 Blood Volume Analyzer is used to diagnose and treat patients in various medical and surgical conditions, including congestive heart failure, critical care medicine and intensive care unit medicine, hypertension, syncope, pre-operative blood screening for hidden anemia, anemia in cancer patients, kidney failure, and hyponatremia. It also provides semen banking, blood storage, andrology, and general lab testing services. Daxor Corporation has a cooperative research and development agreement with the Uniformed Services University of the Health Sciences for researching the effectiveness of BVA-100 diagnostic test on quantifying circulatory blood volume in the context of traumatic injury. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was founded in 1970 and is headquartered in New York, New York.",New York,212 330 8500,NY,1609372800,United States,http://www.daxor.com,86400,Empire State Building,212 244 0806,Medical Instruments & Supplies,Suite 7120 350 Fifth Avenue
